UTHR.NASDAQUnited Therapeutics CORP
Form 4: UNITED THERAPEUTICS CEO Sells Shares
Sentiment:
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on October 2, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on October 2, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 700 Common Stock at $542.06 ($379,443) on October 2, 2026; holds 333,243 after (Indirect).
- Open-market sale: disposed of 408 Common Stock at $542.87 ($221,492) on October 2, 2026; holds 332,835 after (Indirect).
- Open-market sale: disposed of 1,032 Common Stock at $544.17 ($561,588) on October 2, 2026; holds 331,803 after (Indirect).
- Open-market sale: disposed of 1,280 Common Stock at $544.90 ($697,471) on October 2, 2026; holds 330,523 after (Indirect).
- Open-market sale: disposed of 309 Common Stock at $546.75 ($168,945) on October 2, 2026; holds 330,214 after (Indirect).
- Open-market sale: disposed of 1,171 Common Stock at $547.99 ($641,699) on October 2, 2026; holds 329,043 after (Indirect).
- Open-market sale: disposed of 1,206 Common Stock at $548.87 ($661,943) on October 2, 2026; holds 327,837 after (Indirect).
- Open-market sale: disposed of 757 Common Stock at $549.59 ($416,040) on October 2, 2026; holds 327,080 after (Indirect).
- Open-market sale: disposed of 432 Common Stock at $550.99 ($238,027) on October 2, 2026; holds 326,648 after (Indirect).
- Open-market sale: disposed of 725 Common Stock at $551.82 ($400,067) on October 2, 2026; holds 325,923 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $552.86 ($88,457) on October 2, 2026; holds 325,763 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $554.30 ($44,344) on October 2, 2026; holds 325,683 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $555.60 ($44,448) on October 2, 2026; holds 325,603 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $557.43 ($133,784) on October 2, 2026; holds 325,363 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $558.60 ($67,032) on October 2, 2026; holds 325,243 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $560.66 ($67,279) on October 2, 2026; holds 325,123 after (Indirect).
- Open-market sale: disposed of 40 Common Stock at $562.35 ($22,494) on October 2, 2026; holds 325,083 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $563.88 ($45,110) on October 2, 2026; holds 325,003 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $566.58 ($45,326) on October 2, 2026; holds 324,923 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $569.90 ($136,775) on October 2, 2026; holds 324,683 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $570.70 ($68,484) on October 2, 2026; holds 324,563 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $572.44 ($45,795) on October 2, 2026; holds 324,483 after (Indirect).
- Open-market sale: disposed of 40 Common Stock at $574.23 ($22,969) on October 2, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on October 2, 2026; holds 309,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,219,015 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-02 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-10-02 | Open-market sale | Common Stock | 700 | $542 | $379.4K | 333,243 |
| 2026-10-02 | Open-market sale | Common Stock | 408 | $543 | $221.5K | 332,835 |
| 2026-10-02 | Open-market sale | Common Stock | 1,032 | $544 | $561.6K | 331,803 |
| 2026-10-02 | Open-market sale | Common Stock | 1,280 | $545 | $697.5K | 330,523 |
| 2026-10-02 | Open-market sale | Common Stock | 309 | $547 | $168.9K | 330,214 |
| 2026-10-02 | Open-market sale | Common Stock | 1,171 | $548 | $641.7K | 329,043 |
| 2026-10-02 | Open-market sale | Common Stock | 1,206 | $549 | $661.9K | 327,837 |
| 2026-10-02 | Open-market sale | Common Stock | 757 | $550 | $416.0K | 327,080 |
| 2026-10-02 | Open-market sale | Common Stock | 432 | $551 | $238.0K | 326,648 |
| 2026-10-02 | Open-market sale | Common Stock | 725 | $552 | $400.1K | 325,923 |
| 2026-10-02 | Open-market sale | Common Stock | 160 | $553 | $88.5K | 325,763 |
| 2026-10-02 | Open-market sale | Common Stock | 80 | $554 | $44.3K | 325,683 |
| 2026-10-02 | Open-market sale | Common Stock | 80 | $556 | $44.4K | 325,603 |
| 2026-10-02 | Open-market sale | Common Stock | 240 | $557 | $133.8K | 325,363 |
| 2026-10-02 | Open-market sale | Common Stock | 120 | $559 | $67.0K | 325,243 |
| 2026-10-02 | Open-market sale | Common Stock | 120 | $561 | $67.3K | 325,123 |
| 2026-10-02 | Open-market sale | Common Stock | 40 | $562 | $22.5K | 325,083 |
| 2026-10-02 | Open-market sale | Common Stock | 80 | $564 | $45.1K | 325,003 |
| 2026-10-02 | Open-market sale | Common Stock | 80 | $567 | $45.3K | 324,923 |
| 2026-10-02 | Open-market sale | Common Stock | 240 | $570 | $136.8K | 324,683 |
| 2026-10-02 | Open-market sale | Common Stock | 120 | $571 | $68.5K | 324,563 |
| 2026-10-02 | Open-market sale | Common Stock | 80 | $572 | $45.8K | 324,483 |
| 2026-10-02 | Open-market sale | Common Stock | 40 | $574 | $23.0K | 324,443 |
| 2026-10-02 | Option exercise/conversion | Stock Option | 9,500 | — | — | 309,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-02 | Option exercise/conversion (9,500 shares) |
| 2026-10-02 | Open-market sale (700 shares) |
| 2026-10-02 | Open-market sale (408 shares) |
| 2026-10-02 | Open-market sale (1,032 shares) |
| 2026-10-02 | Open-market sale (1,280 shares) |
| 2026-10-02 | Open-market sale (309 shares) |
| 2026-10-02 | Open-market sale (1,171 shares) |
| 2026-10-02 | Open-market sale (1,206 shares) |
| 2026-10-02 | Open-market sale (757 shares) |
| 2026-10-02 | Open-market sale (432 shares) |
| 2026-10-02 | Open-market sale (725 shares) |
| 2026-10-02 | Open-market sale (160 shares) |
| 2026-10-02 | Open-market sale (80 shares) |
| 2026-10-02 | Open-market sale (80 shares) |
| 2026-10-02 | Open-market sale (240 shares) |
| 2026-10-02 | Open-market sale (120 shares) |
| 2026-10-02 | Open-market sale (120 shares) |
| 2026-10-02 | Open-market sale (40 shares) |
| 2026-10-02 | Open-market sale (80 shares) |
| 2026-10-02 | Open-market sale (80 shares) |
| 2026-10-02 | Open-market sale (240 shares) |
| 2026-10-02 | Open-market sale (120 shares) |
| 2026-10-02 | Open-market sale (80 shares) |
| 2026-10-02 | Open-market sale (40 shares) |
| 2026-10-02 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.